Porcupine inhibition: a novel disease-modifier target in arrhythmogenic cardiomyopathy

References

[1] Corrado D,Zorzi A.Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria.Int J Cardiol2020;319:106-14

[2] Austin KM,Chandler SF.Molecular mechanisms of arrhythmogenic cardiomyopathy.Nat Rev Cardiol2019;16:519-37 PMCID:PMC6871180

[3] Garcia-Gras E,Giocondo MJ.Suppression of canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy.J Clin Invest2006;116:2012-21 PMCID:PMC1483165

[4] Cheedipudi SM,Rouhi L.Pharmacological suppression of the WNT signaling pathway attenuates age-dependent expression of the phenotype in a mouse model of arrhythmogenic cardiomyopathy.J Cardiovasc Aging2021;1:3

[5] Musunuru K.Genome Editing: The recent history and perspective in cardiovascular diseases.J Am Coll Cardiol2017;70:2808-21 PMCID:PMC5742864

[6] Rouhi L,Cheedipudi SM.The EP300/TP53 pathway, a suppressor of the Hippo and canonical WNT pathways, is activated in human hearts with arrhythmogenic cardiomyopathy in the absence of overt heart failure.Cardiovasc Res2021;cvab197:

[7] Daskalopoulos EP.Effect of interventions in WNT signaling on healing of cardiac injury: a systematic review.Cells2021;10:207 PMCID:PMC7912185

[8] Manolagas SC.Gone with the Wnts: beta-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism.Mol Endocrinol2007;21:2605-14